Preliminary JYNNEOS Vaccine Effectiveness Estimates Against Medically Attended Mpox Disease in the U.S., August 15, 2022 – October 29, 2022

JYNNEOS vaccine is effective at reducing the risk of mpox disease, with two doses providing the best protection, regardless of how the vaccine was administered.

VE of JYNNEOS against medically attended mpox disease

Preliminary vaccine effectiveness (VE) of JYNNEOS against medically attended mpox disease
	Adjusted VE % (95% CI)
Full vaccination (2 doses)	69 (48, 81)
Males only	67 (45, 80)
Males only, 18-49 years, no history of ACAM2000 vaccination	60 (33, 77)
No immunocompromising conditions	74 (52, 86)
2 doses administered subcutaneously	53 (-14, 81)
2 doses administered intradermally	66 (-50, 92)
2 doses administered heterologously	87 (64, 95)

Partial vaccination (1 dose)	37 (23, 49)
Males only	36 (21, 49)
Males only, 18-49 years, no history of ACAM2000 vaccination	38 (21, 51)
No immunocompromising conditions	38 (19, 52)
1 dose administered subcutaneously	33 (15, 47)
1 dose administered intradermally	38 (0, 62)

These unpublished data are from a matched case control study where cases are patients with an mpox diagnosis or positive laboratory result and controls are patients with an incident HIV diagnosis or HIV pre-exposure prophylaxis prescription. Data are subject to change.

Notes: This study was done in collaboration with Epic Research using data from Cosmos.